In May 2024, Dr. Reddy’s and Alvotech entered into a License and Supply Agreement for AVT03. Under the agreement, Alvotech is responsible for the development and manufacturing of AVT03, while Dr ...

HYDERABAD, India & REYKJAVIK, Iceland, March 18, 2025--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along ...

Hyderabad-based Dr Reddy’s said it will also get exclusive commercial rights to market BAT2206 in Colombia as part of the deal. BAT2206 inhibits the bioactivity of human IL-12 and IL-23, both of ...